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Abstract 
This paper reports the purification of a novel pro-opiomelanocortin derivative peptide (a y-melanocyte stimulating hormone-like (y-MSH-like) 
molecule) from the brain of the leech Theromyzon tessulatum. After reverse-phase HPLC purification, the sequence of the y-MSH-like peptide 
(YVMGHFRWDKFamide) was established by a combination of automated Edman degradation, electrospray mass spectrometry measurement, 
enzymatic treatment and co-elution experiments in reverse-phase HPLC with synthetic peptides. 
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1. Introduction 
Processing of pro-opiomelanocortin (POMC) yields a 
number of bioactive peptides including adrenocorti- 
cotropin, lipotropins, @-endorphin and melanotropins 
(cc-, jY- and y-MSH) [l]. These peptides have been iso- 
lated throughout vertebrates [2-4]. The POMC cDNa 
and gene have been characterized in a variety of mam- 
mals (bovine, murine and rat), including human [5--g]. 
In contrast, no peptide belonging to the POMC family 
has so far been isolated in an invertebrate. However, it 
has been shown in the molluscs Aplysia californica and 
Lymnaea stagnalis that the deduced peptide sequence 
from the isolated FMRF gene [lO,l l] contains, besides 
a series of FMRFamides and FLRFamides, other se- 
quences exhibiting ca. 30% sequence homologies to 
MSH, corticotropin releasing factor (CRF) and corti- 
cotropin-like intermediary pituitary peptide (CLIP). 
Comparable results were obtained in the insect Droso- 
phila where the FMRF gene exhibits ca. 30% sequence 
homology with mammalian CRF [12]. 
In annelids, cells immunoreactive to an antiserum 
raised against y-MSH (a-y-MSH) have been detected in 
the brain of the leech Theromyzon tessulatum [13,14]. A 
category of these immunoreactive cells, the /I giant cells, 
also immunoreacted positively with a polyclonal antise- 
rum directed against angiotensin II (a-AII) and with a 
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Abbreviations: DIA, dot immunobinding assay; ESMS, electrospray 
mass spectrometry; HPLC, high performance liquid chromatography; 
MSH, melanocyte stimulating hormone; R,, retention time; TFA, tri- 
fluoroacetic acid. 
monoclonal antibody (Tt159) specific for epitopes con- 
tained in II: tessulatum supraesophageal ganglia extracts 
[14]. The three epitopes recognized by a-y-MSH, a-AI1 
and Tt159 in the j? giant cells are different [ 141 and borne 
on the same multipeptidic protein of ca. 19 kDa [ 151. One 
of the three epitopes present in this protein, the angioten- 
sin II-like one, has recently been isolated [15]. We now 
report the full characterization in an invertebrate of a 
peptide of the melanotropin family: the y-MSH-like pep- 
tide of i? tessulatum. 
2. Materials and methods 
2.1. Animals 
Mature specimens of the rhynchobdellid leech ‘IY tessulatum, reared 
under laboratory conditions as described by Malecha et al. [16], were 
used in this study. 
2.2. Antiserum 
A rabbit polyclonal antiserum specifically directed against the car- 
boxy-terminus of mammalian I-MSH (a-y-MSH) and kindly provided 
by Dr. G. Tramu (Laboratoire de Neurocytochimie fonctionnelle, 
Universite de Bordeaux I, Talence, France), was used for immunoas- 
says. 
2.3. Immunoassays 
Enzyme-linked immunosorbent assays (ELISA) and dot immuno- 
binding assays (DIA) were conducted according to Salzet et al. [17,18] 
with a I-MSH employed at a dilution of l:l,OOO. As a control, pread- 
sorption of y-MSH was carried out using an homologous peptide. Prior 
to ELISA and DIA, a-y-MSH, at its working dilution, was incubated 
overnight at 4°C with synthetic I-MSH (Sigma) (100 @ml undiluted 
a-y-MSH). 
2.4. Purification 
After anaesthesia of the animals in 0.01% chloretone, 4,000 brains 
were excised. immediatelv frozen in liquid nitrogen and stored at -70” C 
until use. Batches of 404 brains were-homogenized and extracted with 
400 ~1 1 M acetic acid at 4°C. After centrifugation at 12,000 rpm for 
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30 min at 4°C the pellet was re-extracted once. The two supernatants 
were combined and loaded onto Sep-Pak Cls cartridges (500 ~1 extract/ 
cartridge; Waters). After washing the cartridges with 5 ml 1 M acetic 
acid, elution was performed with 5 ml 50% acetonitrile in water acidi- 
fied with 0.1% trifluoroacetic acid (TFA; Pierce). The eluted fractions 
were reduced 20-fold in a vacuum centrifuge (Savant) to remove acid 
and organic solvent. The total amount of y-MSH-like material was 
quantified using ELISA. The 50% eluted fraction was made up to 
250 ~1 with acidified water (0.1% TFA) and fractionated on a Cis 
peptide protein column (250 x 4.6 mm; Vydac) equilibrated with acidi- 
fied water (0.1% TFA). Elution was performed with a discontinuous 
linear gradient of acetonitrile in acidified water over O-15% for 10 min 
and over 1545% for 30 min at a flow rate of 1 ml/mm. The column 
effluent was monitored by absorbance at 226 nm and the presence of 
y-MSH-like material detected on aliquots of each fraction by DIA. The 
fractions that contained the immunoreactive material were applied on 
the same column with a shallower gradient. Elution was performed with 
a linear gradient of 2@-40% acetonitrile in acidified water for 20 min 
at a flow rate of 1 mUmin. After a 20-fold concentration by freeze 
drying, fraction aliquots of 0.5 pl were tested by DIA. The y-MSH-like 
material was finally purified on an ODS C,, reverse-phase column 
(Ultrasphere, 250 x 2 mm; Beckman) developed with a linear gradient 
of &60% acetonitrile in acidified water for 60 min at a flow rate of 50 
pl/min. The column e&tent was monitored by absorbance at 226 nm 
and the immunoreactive material detected as above. 
Co-elutions in reverse-phase HPLC were performed with synthetic 
MSH peptides (a, /I, y) purchased from Sigma and with synthetic 
carboxy-terminus amidated leech y-MSH-like peptide purchased from 
Neosystem. 
All HPLC purifications were performed with a Beckman Gold 
HPLC system equipped with a photodiode array detector Beckman 
168. 
2.5. Structure determination 
Prior to microsequencing, the purity of the peptide was controlled by 
capillary electrophoresis. Separation was performed on an Applied 
Biosystems model 270A-HT capillary electrophoresis ystem. Silica 
capillary (72 cm length) was used. Under these conditions, separation 
was achieved from anode to cathode in a citrate buffer (20 mM) at pH 
2.5. Detection was at 200 mn, temperature 30°C and the volume in- 
jected 2 nl. 
Automated Edman degradation of the purified peptide and detection 
of phenylthiohydantoin (PTH-Xaa) derivatives were performed on a 
pulse liquid automatic sequenator (Applied Biosystems, model 473A). 
The molecular mass was determined by electrospray mass spectrometry 
(ESMS) using a VG Biotech Bio-Q mass spectrometer (Manchester) as 
described elsewhere [18]. The presence of carboxy-terminus amidation 
was researched by carboxypeptidase A treatment under the conditions 
described by the manufacturer (Boehringer-Mannheim). 
3. Results and discussion 
3.1. Isolation of the y-MSH-like peptide 
4,000 brains were subjected to peptide extraction in 
1 M acetic acid pH 2. ELBA revealed 20.3 f 4.8 fmol 
y-MSH-like material/brain in the crude extract (‘prepuri- 
fied using Sep-Pak Ci, cartridges). The fraction eluted by 
50% acetonitrile was reduced 20-fold by freeze drying 
and applied to a Cl8 peptide protein column. Eluted frac- 
tions tested in DIA revealed an immunoreactive zone at a 
retention time (RT) between 27 and 28 min (corresponding 
to 32-33% of acetonitrile) (Fig. 1). The total amount of 
y-MSH-like material determined by ELISA at this step of 
the purification was 15.7 + 3.1 fmol/brain (recovery ca. 
78% of the starting material). Results obtained after pread- 
sorption of a-y-MSH by synthetic y-MSH established 
the specificity of the immunodetection. 
The immunoreactive zone containing the y-MSH-like 
material was analyzed on the same column with a more 
resolutive gradient. A peak immunoreactive to a-y- 
MSH, with a RT between 13 and 13.4 min (corresponding 
to 2626.8% acetonitrile), was resolved. At this step of 
the purification, quantification by ELBA indicated 
12.3 + 4.6 fmol y-MSH-like materiafirain (recovery ca. 
61% of the starting material). This peak was then puri- 
fied to homogeneity on an ODS Cl8 reverse-phase col- 
umn and gave at a RT of 38.8 min. The purity of the 
immunoreactive material was established by capillary 
electrophoresis (Fig. 2). Quantification by ELISA at 
this step of the purification indicated 11.6 * 2.3 fmol 
y-MSH-like material/brain (final recovery of ca. 57%). 
Co-injection in an ODS C,, reverse-phase HPLC col- 
umn of the purified y-MSH-like peptide with a synthetic 
vertebrate melanotropin (a-, /3- or y-MSH) revealed, 
after elution, two peaks, whatever the vertebrate mela- 
notropin co-injected. This result suggested that the leech 
y-MSH-like peptide possesses a structure different from 
the ones of a-, fi- and y-MSH. 
3.2. Characterization of the y-MSH-like peptide 
The amino acid sequence determinated by automated 
Edman degradation of the lY tessulatum y-MSH-like 
peptide is: Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Lys- 
Phe. The two following cycles (12 and 13) did not reveal 
any further PTH-Xaa signals, which indicated the end of 
the peptide. 
The molecular mass of the y-MSH-like peptide meas- 
ured by ESMS (m/z = 1484.2) differed by 1 Da from the 
monoisotopic molecular mass (1485.7 Da) calculated 
from the amino acid sequence determined by Edman 
degradation. This result predicted that the leech y-MSH- 
like peptide possesses an amidated carboxy-terminus, the 
calculated monoisotopic molecular mass of y-MSHa- 
mide-like peptide being 1484.7 Da. In order to determine 
whether the carboxy-terminus of the peptide is blocked 
by amidation, treatment of the purified y-MSH-like pep- 
tide with carboxypeptidase A was performed, but it did 
not affect the retention in reversed-phase HPLC. Moreo- 
ver, co-injection in reverse-phase HPLC of both the puri- 
Table 1 
A comparison of the sequences of i? tessulatum y-MSH-like peptide 
and y,-MSH of different species of vertebrates 
Species Name Structure Refer- 
ences 
Mammal 1 5 10 
Human y,-MSH YVMGHFRWDEF(NH,) WI 
Amphibians 
Xenopus laevis y,-MSH YVM~HFR~F(NH2) 141 
Rana ridibunda y,-MSH ~YVM~HFRWDKF(NH2) 121 
Leech 
Z tessulatum y-MSH-like YVMGHFRWDKF(NH2) 
Amino acids underlined represent those differing from the leech 
y-MSH-like sequence 
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Fig. 1. Separation of a brain extract of Z tessulatum by reverse-phase HPLC. The solid bar indicates the material immunoreactive to a-y-MSH. 
fied and the synthetic carboxy-terminus amidated y- 
MSH-like peptides indicated that a single peak was 
eluted at 38.2 min. These results were consistent with the 
following structure for the ?Y tessulatum y-MSH- 
like peptide: Tyr-Val-Met-Gly-His-Phe-Arg-Trp-Asp-Lys- 
Pheamide. 
The characterization of a y-MSH-like peptide in the 
leech i’Y tessulatum constitutes the first report on the 
presence of a peptide of the melanotropin family in the 
brain of an invertebrate. Indeed, so far in invertebrates, 
only a partial purification of an a-MSH-like peptide in 
the insect Locusta migratoria [19] has been reported. 
The sequence of i? tessulatum y-MSH-like peptide is 
close to the y,-MSH peptides isolated throughout the 
animal kingdom. A sequence alignment of the different 
y,-MSH peptides with i? tessulatum y-MSH-like peptide 
(Table 1) indicated that the y-MSH-like peptide differs 
from human y,-MSH [20] by only one amino acid resi- 
due at position 10 (Lys residue in r tessulatum y-MSH- 
like peptide and Arg in human yi-MSH) and from am- 
phibians (Rana ridibunda and Xenopus Iaevis) yi-MSH 
by two residues. In Rana ridibunda [2], the y,-MSH has 
a NH,-terminus extended by a Lys residue and a Gly at 
position 4. In Xenopus laevis [4], the yi-MSH has two 
amino acid residues different from the i? tessulatum y- 
MSH-like peptide (Thr-4 and Asn-9 for the yl-MSH, a 
Gly-4 and Asp-9 for the y-MSH-like peptide). The data 
deduced from molecular biology experiments (Table 2) 
have confirmed biochemical results obtained in human 
[20] and amphibians [21]. Moreover, in rat (Table 2), at 
the level of the POMC cDNA, the nucleic acid sequence 
coding for the y,-MSH has been found, although a y,- 
MSH peptide has not been biochemically isolated [23]. 
This result is explained by the fact that in rat, at the level 
of the POMC, the yl-MSH is not flanked by pairs of 
dibasic amino acid residues which represent potential 
sites of proteolytic cleavage by processing enzymes. On 
the other hand, in fishes (salmon and trout), a y,-MSH 
would not exist as the isolation of POMC cDNA re- 
vealed (Table 2) a gap in the nucleic acid sequence coding 
for the y,-MSH [24,25]. 
It thus seems that although it does not exist in fishes, 
the y-MSH has been well conserved in the course of 
evolution. Nevertheless, the structure of POMC, the pre- 
cursor of the y-MSH, seems to have changed in the 
course of evolution. In invertebrates, the existence of 
POMC has yet to be demonstrated. In the leech 2: tessu- 
latum, the y-MSH-like peptide would be localized on a 
Table 2 
Alignment of the y,-MSH derived-peptides deduced from POMC 
cDNA isolated from different species of vertebrates 
Species Sequence Refer- 
ences 
Human NPUYVMGHFRWDRFGUNS 1211 
Rat NPKRYVMGHFRWDRFGPRNS 
Xenopus SIGYVMTHFRWNKFGRRNS 
t231 
1221 
Salmon, 124,251 
trout s __--__--- gap --_---------- > 
The dibasic amino acid residues underlined represent potential sites of 
proteolytic cleavage by processing enzymes; gap, no amino acid resi- 
dues corresponding to a y-MSH were found in sequences deduced from 
cDNA sequences coding for POMC. 
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Fig. 2. Capillary electrophoresis of purified Z tessulatum y-MSH-like peptide. Analyses were performed on a 72 cm capillary in 20 mM citrate buffer 
at pH 2.5. 
precursor which bears other peptides [15]. One of these 
peptides, the angiotensin IIamide, has recently been iso- 
lated in leeches (unpublished data). These results favor 
the idea that the POMC-like protein in leeches would be 
different to the one isolated in vertebrates. 
3.3. Physiological function 
The physiological function of the leech cerebral 
y-MSH-like peptide remains to be determined. However, 
an involvement of this peptide in the regulation of the 
color change can be suggested. Indeed, control by the 
central nervous system of this phenomenon in leeches 
has been established [26-291. Moreover, in vertebrates 
the overall role of y-MSH peptides in the regulation of 
pigmentation, although small, exists [30-321. It has been 
suggested that selected y-MSH peptides could modulate 
pigmentation by modifying the cellular response to other 
melanotropins [33]. As the structure of the y-MSH-like 
peptide is close to that of vertebrate yl-MSH, we suspect 
that this peptide has conserved its biological function in 
the course of evolution. 
Acknowledgements: We are indebted to Dr. J. Hoffmarm (Institut de 
Biologie Mol&xlaire et Cellulaire, UPR 9022 CNRS, Strasbourg, 
France) for facilities provided to us for peptide sequencing. We would 
also like to thank Dr. A. Van Dorsselaer (Laboratoire de spectrometrie 
de masse bioorganique, UA 31 CNRS, Strasbourg, France) for the 
mass spectrometry determination. 
References WI 
[1] Mains, R.E., Eipper, B.A. and Ling, N. (1977) Proc. Natl. Acad. 
Sci. USA 74, 3014-3018. 
[2] Tranchand Bunel, D., Conlon, J.M., Chartrel, N., Tonon, M.-C. 
and Vaudry, H. (1992) Mol. Brain Res. 15, l-7. 
[3] Fenger, M. (1988) Regul. Pept. 20, 345-357. 
[4] Rouille, Y., Michel, G., Chauvet, M.T., Chauvet, J. and Acher, R. 
(1989) FEBS Lett. 245, 215-218. 
151 
161 
VI 
PI 
191 
WY 
[ill 
WI 
1131 
[I41 
1151 
V61 
1171 
W31 
u91 
PO1 
WI 
~231 
1241 
1251 
WI 
Nakanishi, S., Inoue, A., Kita, T., Nakamura, M., Chang, A.C.Y., 
Cohen, S.N. and Numa, S. (1979) Nature 278,4233427. 
Uhler, M. and Herbert, E. (1983) J. Biol. Chem. 258, 257- 
261. 
Nakanishi, S., Teranishi, Y., Watanabe, Y., Notake, M., Noda, 
M., Kakidani, H., Jingami, H. and Numa, S. (1981) Eur. J. Bio- 
them. 115,429-438. 
Cachet, M., Chang, A.C.Y. and Cohen, S.N. (1982) Nature 297, 
335-338. 
Notake, M., Tobimatsu, T., Watanabe, Y., Takahashi, H., 
Mishina, M. and Numa, S. (1993) FEBS Lett. 156, 67-71. 
Taussig, R. and Scheller, R. (1986) DNA 5, 453462. 
Linacre, A., Kellett, E., Saunders, S., Bright, K., Benjamin, P.R. 
and Burke, J.F. (1990) J. Neurosci. 10,412419. 
Schneider, L.E. and Taghert, P.H. (1988) Proc. Natl. Acad. Sci. 
USA 85, 1993-1997. 
Verger-Bocquet, M., Malecha, J., Wattez, C. and Tramu, G. 
(1988) Comp. Endocrinol. (Life Sci. Adv.) 7, 21-27. 
Verger-Bocquet, M., Wattez, C., Salzet, M. and Malecha, J. (1992) 
Can. J. Zool. 70, 856865. 
Salzet, M., Wattez, C., Baert, J.-L. and Malecha, J. (1993) Brain 
Res. 631, 247-255. 
Malecha, J., Verger-Bocquet, M.A. and Tramu, G. (1989) Can. J. 
Zool. 67, 636640. 
Sal&, M., Wattez, C., Slomianny, M.C., L&i, B. and Siegert, K.J. 
(1992) Comp. Biochem. Physiol. 102C, 483487. 
Salzet, M., Bulet, P., Van Dorsselaer, A. and Malecha, J. (1993) 
Eur. J. Biochem. 217, 897-903. 
Schoofs, L., Jegou, S., Andersen, A.C., Tonon, M.C., Eberle, 
A.N., Huybrechts, R., De Loof, A. and Vaudry, H. (1988) Brain 
Res. 450, 202-208. 
Roselli-Rehfuss, L., Mountjoy, K.G., Robbins, L.S., Mortrud, 
M.T., Low, M.J., Tatro, J.B., Entwistle, M.L., Simerly, R.B. and 
Cone, R.D. (1993) Proc. Natl. Acad. Sci. USA 90, 88568860. 
Takashia, A., Teranishi, Y., Nakanishi, S. and Numas, S. (1981) 
FEBS Lett. 135, 97-102. 
Martens, G.J.M., Civellio, 0. and Herbert, E. (1985) J. Biol. 
Chem. 260, 13685-13689. 
Drouin, J. and Goodman, H.M. (1980) Nature 288, 61&613. 
Kawauchi, H. (1983) Arch. Biochem. Biophys. 227, 343350. 
Kitahara, N., Nishiiwa, T., Lida, K., Okazaki, H., Andoh, T. and 
Soma, G.I. (1988) Comp. B&hem. Physiol. 9lB, 365-370. 
Smith, R.I. (1942) Physiol. Zool. 15, 41@417. 
106 M. Salzet et al. IFEBS Letters 348 (1994) 102-106 
[271 Gersch, M. and Richter, K. (1961) Zool. J. (Allg. Zoo].) 69, 273- 
284. 
[28] Sawyer, R.T. (1986) Leech Biology and Behavior, pp. 144-148, 
Oxford Science, Oxford. 
[29] Slominski, A., Costantio, R., Worstman, J., Paus, R. and Ling, N. 
(1992) Life Sci. 50, 1103-l 108. 
[30] Eberle, A.N. (1988) in: The Melanotropins: Chemistry, Physiology 
and Mechanism of Action, Karger, New York. 
[31] McCormack, A.M., Carter, R.J., Thody, A.J. and Shuster, S. 
(1982) Peptides 3, 13-16. 
[32] O’Donohue, T.L., Handelmann, G.E., Loh, Y.P., Olton, D.S., 
Leibrowitz, J. and Jacobwitz, D.M. (1981) Peptides 2, 193-200. 
[33] Slominski, A., Paus, R. and Worstman, J. (1993) Mol. Cell. En- 
doer. 93, Cl-C6. 
